Cannabis Law Report

JANUARY 3, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. There is a large and growing need to treat acute cannabinoid intoxication with 1.7 million cannabinoid-related emergency department visits in the U.S. About Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Cannabis Law Report

DECEMBER 23, 2021

DUBLIN–(BUSINESS WIRE)– “The Pharmaceutical Cannabis Report: 2nd Edition” report has been added to ResearchAndMarkets.com’s offering. This report has been compiled to assist interested parties in understanding the market for the medical use of cannabinoids and where it may be heading. GW Pharmaceuticals.

Pharmaceutical 96

Pharmaceutical Clinical Trials Research and Development Cannabinoids 96

Canna Care Docs

NOVEMBER 4, 2024

Patients dealing with chronic pain from numerous conditions are finding relief in cannabis. Healthcare, tennis player and injured black man or athlete with muscle pain or inflammation after exercise or workout Chronic Pain and Challenges Chronic pain is a long-lasting condition that persists for more than 3-6 months, sometimes lasting years.

Chronic Pain 111

Chronic Pain Nerve Pain Treatment Cannabinoids 111

Veriheal

AUGUST 12, 2021

million people across the United States , report experiencing improved quality of life and a more restful night’s sleep after consuming the non-psychoactive cannabinoid CBD (cannabidiol). Patients who suffer from epilepsy , which affects some 3.4 CBD, which constitutes a $2,770.8 It goes by the name of “artisanal CBD.” .

Epilepsy 81

Epilepsy Pharmaceutical Patients Sleep 81

Peninsula Alternative Health

MAY 15, 2019

As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because cannabis is still a schedule 1 drug in the U.S.,

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

Cannabis Law Report

AUGUST 10, 2021

We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Cannabis Law Report

JANUARY 6, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. About Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Cannabis Law Report

NOVEMBER 12, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. 11,141,404, titled “Formulations And Methods For Treating Acute Cannabinoid Overdose.” ” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

JANUARY 4, 2022

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. Our lead product, ANEB-001, has the potential to rapidly reverse the effects of acute cannabinoid intoxication, a relatively unknown yet serious affliction that sends more than 5,000 Americans to the hospital emergency department every day.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Cannabinoids 52

Cannabis Law Report

SEPTEMBER 22, 2021

Oxford Cannabinoid Technologies Holdings plc. . Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. OCT’s second programme uses inhaled phytocannabinoids to target an undisclosed orphan pain condition, with Phase 1 trials also scheduled for Q3 2022 and Phase 2 expected in Q2 2023.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

JUNE 1, 2022

Pharmadrug GmbH has been active worldwide for almost 40 years as a manufacturer and wholesaler of medicinal products and active pharmaceutical ingredients. Our team in Europe is excited to join forces with new colleagues from Pharmadrug GmbH, with their valuable expertise in the German pharmaceutical market.”

Pharmaceutical 52

Pharmaceutical Medicine Extraction Cannabinoids 52

Project CBD

MAY 3, 2023

Goldstein will be leading the Medical Practicum at CannMed 2023 (May 15-17), where she will also be speaking about CBG and other minor cannabinoids during the main session. You have said that cannabigerol, or CBG, is one of your favorite cannabinoids. Is that because CBG is a precursor for the other plant cannabinoids?

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

PrestoDoctor

DECEMBER 12, 2023

Additionally, cannabis has shown promise in easing symptoms of chronic conditions such as arthritis, insomnia, and anxiety. Additionally, using cannabis for medical conditions does not mean THC must be consumed. CBD also plays an important role in management of conditions without the psychoactive high.

Medicine 98

Medicine Chronic Pain Consumption Pharmaceutical 98

United Patients Group

FEBRUARY 7, 2023

Inflammation can lead to a wide range of diseases and conditions, including heart disease, arthritis and cancer. This article will cover some common uses for medical cannabis when treating inflammation or pain along with what other ingredients might be helpful in reducing symptoms related to these conditions!

Cannabinoids 116

Cannabinoids Chronic Pain Terpenes THC 116

Cannabis Law Report

NOVEMBER 12, 2021

THE Chairman of a recently-listed UK pharmaceutically-focused cannabis company has stood down after a breach of market rules. Neil Mahapatra is a co-founder of the Oxford Cannabinoid Technologies (OCT) which floated on the LSE in the May this year, he is also founder of UK venture capital business Kingsley Capital Partners (KCP).

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. Epidyolex has been approved as a treatment option for children as young as two with Lennox-Gastaut syndrome or Dravet syndrome – difficult-to-treat conditions that can cause multiple seizures a day. ” Source BBC: [link].

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

DECEMBER 1, 2021

Cannabis and Life Sciences Company Initiates Internal Study Comparing Anti-Inflammatory Properties of Candidate JUVA-019 When Combined With Cannabinoids Such as THC and CBD. who has an extensive background in pharmaceutical research and development. November 30, 2021 04:00 ET | Source: Juva Life Inc.

Cannabinoids 52

Cannabinoids Research and Development Pharmaceutical THC 52

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. Chris Chapman, M.D.,

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. minor cannabinoids market size is expected to reach USD 26.2

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Cannabis Law Report

NOVEMBER 17, 2022

This collaboration ensures first-of-their-kind consistent cannabinoid compositions for 575 DEA-licensed cannabis medical research institutions developing cures for PTSD, pain management, anxiety conditions and more Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp.

Pharmaceutical 52

Pharmaceutical Research and Development DEA Cannabinoids 52

Veriheal

JANUARY 26, 2023

Bipolar disorder is a complex condition that impacts millions worldwide, leading to extreme mood swings, intense emotional episodes, and difficulty managing day-to-day life. Most commonly, pharmaceutical medication is prescribed to regulate moods. But there may be some good news for those coping with this mental health issue.

Treatment 98

Treatment Cannabinoids Conditions Pharmaceutical 98

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

SpeedWeed

MAY 10, 2021

If you or a loved one suffer from depression, rare cannabinoid CBC (cannabichromene) may offer hope for a happier future. The third most prevalent cannabinoid in hemp and cannabis, CBC’s mood-elevating properties are about ten times more effective than CBD, making it a promising cannabinoid for reducing stress.

Cannabinoids 52

Cannabinoids Terpenes Tincture Oil 52

Cannabis Law Report

JULY 12, 2019

International Cannabinoid Cancer Research Institute (Draft 5). This paper seeks to answer why refined cannabinoids have more side effects than the natural cannabis product, as well as the possible etiology of said adverse reactions. Also discussed are other attempts at affecting the cannabinoid system from a singular standpoint.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Veriheal

APRIL 7, 2022

As with many other conditions, there is a lack of research regarding the use of MMJ as an alternative treatment to relieve symptoms of MS. . The researchers suggest that the cannabinoids in MMJ can assist with the treatment of MS, contributing “add-on immunosuppressive, analgesic, neuroprotective and remyelinative effects.”

Patients 98

Patients Treatment Cannabinoids Pharmaceutical 98

Veriheal

OCTOBER 13, 2020

Ulcerative Colitis is a condition that causes long-lasting inflammation and ulcers (sores) in the innermost lining of the individual’s large intestine and rectum. Crohn’s Disease is also a condition that causes inflammation, but it affects the lining of the digestive tract, which can then spread deeply into the affected tissues. .

Digestion 123

Digestion Treatment Conditions Research and Development 123

MMJ Recs

JULY 11, 2024

Medical marijuana is a potential treatment for insomnia, and it offers an alternative to traditional pharmaceuticals. It can be caused by a variety of factors, including medical conditions, psychological issues, or environmental factors. It can be caused by underlying health conditions, medications, or psychological factors.

Sleep 111

Sleep Treatment Research and Development Therapy 111

Veriheal

AUGUST 9, 2023

Recent research reaffirms earlier studies that claim that certain non-marijuana plants contain similar compounds found in cannabis, often called cannabinoids. Even more, CBD is the first FDA-approved pharmaceutical drug for two rare forms of epileptic seizures in kids.

CBD 96

CBD Cannabinoids THC Extraction 96

The Cannigma

FEBRUARY 1, 2023

Individuals who use cannabis-based medications often want to cure their cancer, not just reduce the symptoms that come with the condition. Even if a cannabinoid has shown promise on one cancer line, that doesn’t mean it will work for all cancers – even if it’s within the same organ system. 1 So can cannabis cure cancer?

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

FloridaMarijuana.net

JUNE 22, 2018

Patients who suffer from this condition also face other symptoms that are painful, inconvenient -to say the least, -and lower their quality of life. Many of these medications have serious side effects that only add on to the stress, pain, and frustration that patients already feel due to their condition.

Hybrid 189

Hybrid Marijuana Sativa Nerve Pain 189

United Patients Group

MAY 17, 2023

Introduction Autism spectrum disorder (ASD) is a neurodevelopmental condition that affects communication, social interactions and behaviors. Some researchers believe that cannabinoids may help people with ASD manage anxiety and stress by increasing their ability to focus and pay attention.

Sleep 105

Sleep Cannabinoids Patients CBD 105

MMJ Recs

FEBRUARY 18, 2024

This comprehensive article aims to explore the myriad health benefits of medical marijuana, delving into its therapeutic potential, impact on mental health, role in managing chronic conditions, and the holistic healing it offers, with a special focus on cannabinoids like CBD.

Chronic Pain 52

Chronic Pain Marijuana Epilepsy Research and Development 52

SpeedWeed

MARCH 30, 2021

If you’d like to try it for yourself, you can buy premium, lab-tested delta-8-THC from Rare Cannabinoid Company online and in more than 100 stores nationwide. Rare Cannabinoid Company’s delta-8-THC oil tincture contains 500mg – up to 75 doses – of delta-8-THC per bottle. Courtesy of Rare Cannabinoid Company. What is delta-8-THC?

THC 52

THC Cannabinoids Tincture Oil 52

Cannabis Law Report

AUGUST 6, 2021

CBD, which is an abbreviation for Cannabidiol, is one of Cannabis’s primary components – one of its primary Cannabinoids. Cannabinoids are the naturally occurring compounds found in the Cannabis plant. There are over 480 different Cannabinoids in the Cannabis plant. It is non-psychoactive and has a multitude of health benefits.

CBD 105

CBD Wellness and Beauty Treatment Pharmaceutical 105

CannaMD

FEBRUARY 19, 2020

Post-traumatic stress disorder (PTSD) is a condition most often associated with military veterans, but it is not confined to wartime experiences. Medical Marijuana: More Effective Than Pharmaceuticals? To date, there is no pharmaceutical product targeted specifically for the treatment of PTSD.

CBD 92

CBD Pharmaceutical Research and Development Conditions 92